Six-month data from the ESPRIT trial show that Abbott’s Esprit BVS, a peripheral stent based on the same technology as the Absorb BVS, reduces symptoms and keeps arteries open. Biotronik also announced that it has moved into the second phase of an MRI-compatibility trial of its Entovis pacemaker. More research news.

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.